English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

This study, made on 60 chronic mental patients, had aimed to determine the effective dosage of trihexyphenidyl, an antiparkinsonian drug. During the preliminary period all patients were given a standard medication consisting of a neuroleptic, trifluoperazine 60 mg. daily, and an antiparkinsonian agent, trihexyphenidyl 10 mg. daily. A placebo was substituted for the antiparkinsonian during the first experimental period to measure the patients' extrapyramidal sensitivity. This evaluation was performed with a rating scale (B.E.P.) and observations from the nursing staff.    Patients were divided into three groups of 20 according to their B.E.P. score and received one of the three therapeutic regimens: trihexyphenidyl 15 mg. or 6 mg. or placebo.    Analyses of the results allow us to conclude that for this population a daily dosage of 6 mg. of trihexyphenidyl gives as much protection as 15 mg.; patients receiving an antiparkinsonian agent needed less “p.r.n.” administration of prociclydine. We have also found that if the antiparkinsonian drug can control some extrapyramidal symptoms it might be responsible for the presence of other more complex neurological symptoms.

Medication Antiparkinsonienne et Bilan Extra-Pyramidal: Etude du Trihexyphenidyl